109 related articles for article (PubMed ID: 15814666)
1. Fas ligand (CD178) cytoplasmic tail is a positive regulator of Fas ligand-mediated cytotoxicity.
Jodo S; Pidiyar VJ; Xiao S; Furusaki A; Sharma R; Koike T; Ju ST
J Immunol; 2005 Apr; 174(8):4470-4. PubMed ID: 15814666
[TBL] [Abstract][Full Text] [Related]
2. Novel negative regulator of expression in Fas ligand (CD178) cytoplasmic tail: evidence for translational regulation and against Fas ligand retention in secretory lysosomes.
Xiao S; Deshmukh US; Jodo S; Koike T; Sharma R; Furusaki A; Sung SS; Ju ST
J Immunol; 2004 Oct; 173(8):5095-102. PubMed ID: 15470053
[TBL] [Abstract][Full Text] [Related]
3. Combination of molecular mimicry and aberrant autoantigen expression is important for development of anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus.
Mihara S; Suzuki N; Takeba Y; Soejima K; Yamamoto S
Clin Exp Immunol; 2002 Aug; 129(2):359-69. PubMed ID: 12165095
[TBL] [Abstract][Full Text] [Related]
4. Separate domains of the human fas ligand dictate self-association and receptor binding.
Orlinick JR; Elkon KB; Chao MV
J Biol Chem; 1997 Dec; 272(51):32221-9. PubMed ID: 9405425
[TBL] [Abstract][Full Text] [Related]
5. Binding of the intracellular Fas ligand (FasL) domain to the adaptor protein PSTPIP results in a cytoplasmic localization of FasL.
Baum W; Kirkin V; Fernández SB; Pick R; Lettau M; Janssen O; Zörnig M
J Biol Chem; 2005 Dec; 280(48):40012-24. PubMed ID: 16204241
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of Fas ligand by shedding.
Tanaka M; Itai T; Adachi M; Nagata S
Nat Med; 1998 Jan; 4(1):31-6. PubMed ID: 9427603
[TBL] [Abstract][Full Text] [Related]
7. Fas ligand is targeted to secretory lysosomes via a proline-rich domain in its cytoplasmic tail.
Blott EJ; Bossi G; Clark R; Zvelebil M; Griffiths GM
J Cell Sci; 2001 Jul; 114(Pt 13):2405-16. PubMed ID: 11559749
[TBL] [Abstract][Full Text] [Related]
8. The molecular mechanism of FasL-mediated cytotoxicity by CD4+ Th1 clones.
el-Khatib M; Stanger BZ; Dogan H; Cui H; Ju ST
Cell Immunol; 1995 Jul; 163(2):237-44. PubMed ID: 7541726
[TBL] [Abstract][Full Text] [Related]
9. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
Delgado M; Ganea D
J Immunol; 2000 Jul; 165(1):114-23. PubMed ID: 10861043
[TBL] [Abstract][Full Text] [Related]
10. Expression of the functional soluble form of human fas ligand in activated lymphocytes.
Tanaka M; Suda T; Takahashi T; Nagata S
EMBO J; 1995 Mar; 14(6):1129-35. PubMed ID: 7536672
[TBL] [Abstract][Full Text] [Related]
11. Humanization and epitope mapping of neutralizing anti-human Fas ligand monoclonal antibodies: structural insights into Fas/Fas ligand interaction.
Nisihara T; Ushio Y; Higuchi H; Kayagaki N; Yamaguchi N; Soejima K; Matsuo S; Maeda H; Eda Y; Okumura K; Yagita H
J Immunol; 2001 Sep; 167(6):3266-75. PubMed ID: 11544314
[TBL] [Abstract][Full Text] [Related]
12. Molecular cloning, expression and characterization of rhesus macaque Fas ligand cDNA.
Wang W; Asiedu C; George JF; Thomas JM
Hum Immunol; 1998 Oct; 59(10):599-606. PubMed ID: 9757941
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Fas/Fas ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus.
Suzuki N; Ichino M; Mihara S; Kaneko S; Sakane T
Arthritis Rheum; 1998 Feb; 41(2):344-53. PubMed ID: 9485093
[TBL] [Abstract][Full Text] [Related]
14. Negative regulation of CD95 ligand gene expression by vitamin D3 in T lymphocytes.
Cippitelli M; Fionda C; Di Bona D; Di Rosa F; Lupo A; Piccoli M; Frati L; Santoni A
J Immunol; 2002 Feb; 168(3):1154-66. PubMed ID: 11801650
[TBL] [Abstract][Full Text] [Related]
15. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effects on the inhibition of human CD8+ cytotoxic T lymphocytes-mediated killing against xenograft cells by coexpression of membrane-bound Human FasL and decoy Fas antigen.
Tanemura M; Kawamoto K; Ito T; Uchikoshi F; Shimada K; Nishida T; Matsuda H
Transplant Proc; 2005 Dec; 37(10):4607-9. PubMed ID: 16387181
[TBL] [Abstract][Full Text] [Related]
17. IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity In vivo.
Aung S; Graham BS
J Immunol; 2000 Apr; 164(7):3487-93. PubMed ID: 10725701
[TBL] [Abstract][Full Text] [Related]
18. Molecular cloning, characterization, and expression of porcine Fas ligand (CD95 ligand).
Muneta Y; Shimoji Y; Inumaru S; Mori Y
J Interferon Cytokine Res; 2001 May; 21(5):305-12. PubMed ID: 11429161
[TBL] [Abstract][Full Text] [Related]
19. Bioactivities of Fas ligand-expressing retroviral particles.
Jodo S; Strehlow D; Ju ST
J Immunol; 2000 May; 164(10):5062-9. PubMed ID: 10799862
[TBL] [Abstract][Full Text] [Related]
20. Role of cytokines in promoting immune escape of FasL-expressing human colon cancer cells.
Xu T; Sun BC; Li Q; Hao XS
World J Gastroenterol; 2005 Jul; 11(25):3915-9. PubMed ID: 15991293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
